Aqilion

About Us

Aqilion is a biotech company that focuses on developing innovative new treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such asautoimmune diseases. We identify innovative ideas that could potentially lead to new medications and refine them into commercially interesting projects. The ideas that we choose are based on solid scientific grounds, where we, with reasonable assumptions, can understand the underlying biology, clinical relevance and patient benefit. The company is mainly active in the early phases of drug discovery, from idea to proof-of-concept in clinical trials. Aqilion runs its development programs in a partly virtual organization in close collaboration with selected partners with specific expertise in drug development. AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com

Contacts

Sarah Fredriksson

CEO

C/O HETCH AB Redaregatan 48 SE-252 36 Helsingborg Sweden
+ 46 (0)70 261 4575
http://www.aqilion.com
sarah.fredriksson@aqilion.com

Quotes

Our discovery team has been working with several interesting drug targets during the last two years, with the aim to select a new preclinical program. It is exiting to be able nominate PKCtheta and to leverage experiences and successes from Aqilion’s other preclinical and clinical kinase inhibitor programs

Sarah Fredriksson, CEO of Aqilion.

It is very pleasing and strategically important that we have appointed Gustaf as the new CFO. He will bring broad and relevant experience and expertise to enhance the Aqilion’s finance function and contribute to the company's future financing. At the same time, I would like to take the opportunity to thank Torgeir Vaage for his contributions to the company over many years.

Sarah Fredriksson, CEO of Aqilion

We thank our shareholders for their support. The capital injection will primarily be used for our early research projects with focus on new innovative treatments for chronic inflammatory diseases where there is a pronounced medical need, but only few or no treatments

Sarah Fredriksson, CEO of Aqilion

With our new Scientific Advisory Board, three internationally renowned scientists are joining our team as advisors. Both their outstanding scientific and clinical expertise and an active network of researchers in EoE will be invaluable for Aqilion

Sarah Fredriksson, CEO of Aqilion

We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with pro-active business development and early deal-making. We are looking forward to working with Merck as this will speed up the process of bringing novel effective treatments to conditions with high unmet medical needs.

Sarah Fredriksson, CEO of Aqilion

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases

Thu, Aug 11, 2022 07:30 CET

AQILION AB (publ) announces today that the Phase 1 clinical safety study on the drug candidate AQ280 on healthy volunteers has started. The substance AQ280, part of the company’s Regulus development program, is a super selective JAK1 small molecule inhibitor that is under development for indications within chronic inflammatory diseases. Aqilion has thus reached a very important milestone as the company has managed to take the big step from preclinical phase to clinical Phase 1. The Phase 1 clinical trial, ARIA-1, will include 64 healthy volunteers. The purpose of the study is to

There are no items matching the current filter

There are no more items matching the current filter

About Us

Contacts

Quotes

Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases

Subscribe

Media

Rss

Share

About Us

Contacts

Quotes

Aqilion starts Phase 1 clinical trial with drug candidate AQ280 for chronic inflammatory diseases

Subscribe

Media

Rss